SecBot SecBot
Biotech Drug Report Generated Sep 13, 2026

itruvone

VTGN·Vistagen Therapeutics, Inc.
NEUTRAL
Drug Impact Rating2/10
Trial phase
Preclinical / Early-stage (no clinical trials identified)
Time to market
Unknown, likely years away, if ever developed. The company's lead asset fasedienol just failed a Phase 3 trial, and with only ~$31.7M in cash (as of June 30, 2026) burning ~$13.7M/quarter, Vistagen may not have the resources to advance itruvone into the clinic without significant financing.
Why 2/10
Itruvone has no scheduled clinical readout, PDUFA, or other hard binary catalyst within the next ~12 months. It is a preclinical/early-stage pipeline asset at a company with a ~$10M market cap whose lead drug (fasedienol) just failed Phase 3. Itruvone is too early-stage and too small a part of an already-struggling pipeline to drive a material share-price move on its own.
Actionable Insight NEUTRAL

Itruvone is not a tradeable catalyst, it is a preclinical pipeline placeholder at a cash-strapped micro-cap whose lead asset just failed Phase 3. VTGN stock will move on the outcome of the FDA meeting for fasedienol and on financing events, not on itruvone. Avoid trading based on itruvone alone.

Price Chart

Loading chart...

Executive Summary

Itruvone is an early-stage pipeline drug at Vistagen Therapeutics (VTGN), a micro-cap biotech trading around $0.24/share with a ~$10M market cap. The drug is mentioned in SEC filings alongside fasedienol (the company's now-failed Phase 3 social anxiety drug) and refisolone, but no mechanism, indication, clinical trial data, or development timeline has been publicly disclosed. Vistagen is in a precarious financial position with ~$31.7M in cash burning ~$13.7M/quarter after its lead asset fasedienol failed the PALISADE-4 Phase 3 trial in June 2026. Itruvone is too early-stage and too thinly documented to be a meaningful standalone value driver for the stock.

How It Works

Not publicly disclosed. Itruvone is an early-stage pipeline asset at Vistagen Therapeutics, alongside the company's former lead drug fasedienol (a pherine nasal spray for social anxiety disorder) and refisolone. No specific mechanism, indication, or molecular target has been publicly described for itruvone.

Trial Status

Itruvone is listed as a pipeline drug in Vistagen's SEC filings alongside fasedienol and refisolone, but no clinical trials, regulatory filings, or development-stage details are publicly available. The drug appears to be at a very early preclinical stage. No ClinicalTrials.gov records, FDA catalysts, or press releases specifically mentioning itruvone were found in SecBot's ingested databases.

The Two-Sided Case

▲ Bull Case2
Itruvone represents a potential pipeline option value at essentially zero cost, if Vistagen can secure financing or a partnership, it could eventually be developed into a clinical-stage asset.
The company has attracted institutional accumulation from Renaissance Technologies, Morgan Stanley, JPMorgan, and Citigroup in recent quarters, suggesting some sophisticated investors see value in the broader pipeline.
▼ Bear Case4
Itruvone is a preclinical asset with no disclosed mechanism, indication, or clinical data, essentially a 'pipeline filler' with no tangible value for investors.
Vistagen has only ~$31.7M in cash and is burning ~$13.7M/quarter, giving less than 12 months of runway. The company will likely need dilutive financing just to survive, making it unlikely itruvone will ever reach the clinic.
The lead drug fasedienol failed its Phase 3 PALISADE-4 trial (p=0.427), severely damaging investor confidence in the company's pipeline and scientific platform.
Analyst consensus is overwhelmingly negative: 0 Buy, 7 Hold, 1 Sell, 2 Strong Sell, with a weighted short-volume ratio of ~49% indicating heavy bearish positioning.

Upcoming Catalysts

  • No scheduled catalysts identified for itruvone specifically. The company's next major event is an FDA meeting to discuss a potential path forward for fasedienol following its Phase 3 failure.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Vistagen Therapeutics, Inc. PRESS-RELEASE VTGN ·Originating report

Sources · 3

Hover a chip for the title
1 sec.gov2 sec.gov3 sec.gov